Compare HLI & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLI | PODD |
|---|---|---|
| Founded | 1972 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.3B |
| IPO Year | 2015 | 2007 |
| Metric | HLI | PODD |
|---|---|---|
| Price | $124.95 | $144.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 21 |
| Target Price | $194.29 | ★ $341.48 |
| AVG Volume (30 Days) | 942.1K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 6.87 | N/A |
| EPS | 1.15 | ★ 2.67 |
| Revenue | $2,617,516,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $13.77 | $24.55 |
| Revenue Next Year | $12.10 | $19.18 |
| P/E Ratio | $107.09 | ★ $53.52 |
| Revenue Growth | 9.55 | ★ 30.73 |
| 52 Week Low | $112.83 | $126.40 |
| 52 Week High | $211.78 | $354.88 |
| Indicator | HLI | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 38.88 | 38.64 |
| Support Level | $112.83 | $141.67 |
| Resistance Level | $144.92 | $167.98 |
| Average True Range (ATR) | 5.29 | 6.13 |
| MACD | -0.97 | -3.03 |
| Stochastic Oscillator | 38.13 | 35.86 |
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.